Gastroenterology

This is the first US initiative in to address the potential role of screening and isolation of asymptomatic C. difficile carriers in an outbreak setting as an adjunct to standard infection prevention measures.

The therapy, currently approved in oral and injectable formulations, is being considered for adult women with symptoms.

Automatic alerts can reduce unnecessary testing, which might produce false-positives.

Tofacitinib was evaluated for the expansion of its indication based on data from 3 clinical trials.

A recent CDC report shows an association between the increase in HCV infections and the opioid crisis. Because HCV symptoms may not appear for decades, people often go undiagnosed, which delays treatment.

By the time of diagnosis, patients often have costly complications involving the liver.

The agency’s decision was made based on data from 2 phase 3 clinical trials—ADAPT-1 and ADAPT-2—which tested the safety and efficacy of avatrombopag in 435 patients.

It can’t replace two-step laboratory testing, but it is a suitable alternative as a diagnostic tool.

Oral amoxicillin and intravenous ertapenem kill commensal bacteria and increase risk for antibiotic resistance in Clostridium difficile.

Hemospray, from Wilson-Cook Medical, stopped GI bleeding in nearly all patients within 5 minutes of treatment.

An initial high dose or high dose escalation can work best for Clostridium difficile treatment.

FusionVu allows for the fastest and simplest real-time targeting of prostate biopsies while also providing the highest resolution in real-time guidance for them, according to Exact Imaging.

These findings provide health care decision-makers with novel information about the allocation of scarce resources relating to Clostridium difficile.

Evidence has also proven that C. difficile can be found in vegetables.